Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy.

Tamara Gracia CazañaMarta MascaraqueSilvia Rocío LucenaJesús Vera-ÁlvarezSalvador GonzálezÁngeles JuarranzYolanda Gilaberte

Published in: PloS one (2019)

Our finding suggest that certain clinicopathological and immunohistochemical variables, particularly p53 expression, may serve as indicators of BCC response to MAL-PDT, and thus facilitate the selection of patients who are most likely to benefit from this therapy.

Keyphrases

photodynamic therapy
basal cell carcinoma
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
fluorescence imaging
stem cells
patient reported outcomes
mesenchymal stem cells
cell therapy